Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Achieves Historically Low Eight-Month Median Drug Review Time In 2017

Executive Summary

Median review times for US agency's drug center were 10 months from 2011 to 2013, and 11 months from 2015 to 2016.

You may also be interested in...



FDA Reviewers Share CMC, GMP Challenges In Last Year's Rush To Approve New Therapies

Inundated with high-priority applications last year, US FDA's CMC reviewers struggled with seemingly thrown-together review packages, moving-target manufacturing processes and not-on-the-same-page contract manufacturers.

FDA Bests Annual Novel Drug Approval Record With Four Oks In One Week

The agency's Dec. 21 approval of Giapreza became novel drug No. 46 of 2017, topping the 2015 mark of 45.

Keeping Track: US FDA Approves Siliq, Accepts Mylan/Biocon Pegfilgrastim Biosimilar

The latest drug development news and highlights from our FDA Performance Tracker.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS122228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel